COVID-19 Made Moderna Famous: Cancer Could Define Its Future
Key takeaways
- Moderna’s Phase 3 melanoma win could be the catalyst that turns its mRNA platform into a sustainable oncology business, redefining its future beyond COVID‑19.
- Revenue 2021: $19 billion
- Revenue 2022: $20 billion
- Revenue 2023: $7 billion
What happened
Moderna’s personalized mRNA cancer vaccine met primary endpoints in a Phase 3 melanoma trial, the first mRNA‑based cancer treatment to do so. The trial showed that the vaccine, designed from a patient’s tumor, helped the immune system attack remaining cancer cells after surgery. The success signals that Moderna’s mRNA platform could extend beyond COVID‑19 vaccines into oncology. The company also announced similar personalized approaches for lung, bladder and kidney cancers.
Why it matters
The melanoma result gives Moderna a credible, high‑profile oncology success that could redefine its business model after COVID‑19 revenue declined. It validates the mRNA platform for cancer, potentially opening a large new revenue stream and improving long‑term valuation. Investors now have a concrete successor to…
Short-term and longer-term
Short-term. Short‑term traders should watch for Moderna’s next earnings release for detailed Phase 3 data and any guidance on commercialization timelines.
Longer-term. Long‑term investors should evaluate how the melanoma success fits into Moderna’s broader oncology strategy, including pipeline depth, regulatory pathway, and potential market size.